Big Pharma drug manufacturer Celgene Corp. is turning the heads of customers as well as the Department of Health and Human Services due to the constantly rising price of the drug Revlimid, which has increased since 2006 with impunity. Former CEO Robert Hugin even bragged about Celgene’s monopoly to Bloomberg back in 2012, and their practices still haven’t stopped. Ana Kasparian discusses on The Young Turks. Watch LIVE weekdays 6-8 pm ET.
Read more HERE:
“When Celgene Corp. first started marketing the drug Revlimid to treat multiple myeloma in 2006, the price was $6,195 for 21 capsules, a month’s supply.
By the time David Mitchell started taking Revlimid in November 2010, Celgene had bumped the price up to about $8,000 a month. When he took his last month’s worth of pills in April 2016, the sticker price had reached $10,691. By last March, the list price had reached $16,691.
Revlimid appears to have caught the attention of Health and Human Services Secretary Alex Azar, who used it as an example Wednesday — without naming it outright — of how some drug’s prices rise with impunity. He said the copay for the average senior taking the drug rose from $115 to about $690 per month in the last year.”
***
The largest online progressive news show in the world. Hosted by Cenk Uygur and Ana Kasparian. LIVE weekdays 6-8 pm ET.
Help support our mission and get perks. Membership protects TYT’s independence from corporate ownership and allows us to provide free live shows that speak truth to power for people around the world. See Perks: ▶
SUBSCRIBE on YOUTUBE: ☞
FACEBOOK: ☞
TWITTER: ☞
INSTAGRAM: ☞
TWITCH: ☞
👕 Merch:
❤ Donate:
🔗 Website:
📱App:
📬 Newsletters:
If you want to watch more videos from TYT, consider subscribing to other channels in our network:
The Damage Report ▶
TYT Sports ▶
The Conversation ▶
Rebel HQ ▶
TYT Investigates ▶
#TYT #TheYoungTurks #BreakingNews
211222__TA02Drug
The Young Turks
source
